- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03118466
Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia
Phase 2 Study of Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied.
The FDA (the U.S. Food and Drug Administration) has not approved lenalidomide for this specific disease, but it has been approved for other uses, including for patients with multiple myeloma and some patients with myelodysplastic syndrome. This treatment is investigational because it is not approved by the FDA for patients with AML. Lenalidomide is a chemotherapy that also modulates the immune system, and is in a category of drugs called immunomodulatory drugs or IMIDs. Some research studies suggest that lenalidomide may be effective in patients with AML. Since the investigators know that many patients who receive MEC chemotherapy alone have less than desired response rates and overall shorter periods of remission (time free from leukemia) after treatment, the investigators are studying whether the addition of lenalidomide to MEC improves upon typical responses.
The combination of MEC (mitoxantrone, etoposide, and cytarabine) is a standard treatment option, commonly used for relapsed or refractory acute myeloid leukemia.
.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, United States, 02215
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02062
- Dana Farber Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Acute myelogenous leukemia diagnosed by WHO criteria with one of the following (patients with biphenotypic leukemia are eligible, provided that the treating physician determines an AML treatment regimen is appropriate)
- Primary refractory disease following > 1cycle of chemotherapy, (such as hypomethylating agent or induction chemotherapy)
- First relapse or higher. Patients with primary or secondary acute myelogenous leukemia are eligible.
- Age 18-70 years old
- LVEF > 50 %
- ECOG Performance status 0-2
- Able to adhere to study schedule and other protocol requirements.
Participants must have normal organ function as defined below, unless felt due to underlying disease and approved by the overall PI. Patients with Gilbert's disease may have total bilirubin up to < 3 x ULN.
- Creatinine < 2.0mg/dl
- Total bilirubin < 1.5 x ULN
- AST (SGOT) and ALT (SGPT) < 3 x ULN.
- Patients may receive hydroxyurea, steroids, or leukapheresis as necessary until Day 5 of treatment.
- Patients must give voluntary written informed consent and HIPAA authorization before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
- Patients may have had prior treatment for MDS or AML, including prior lenalidomide for MDS or AML or another condition.
- Patient may have had prior autologous or allogeneic transplant (family member, unrelated donor, or cord blood) if there is at least 90 days between transplant and study entry.
- Patients may also have had donor lymphocyte infusion if there is at least 60 days between donor lymphocyte infusion and study entry.
- Patients on immunosuppression are also eligible.
- Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL prior to receiving treatment with lenalidomide, and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy.
- Ability to understand and the willingness to sign a written informed consent document.
- All study participants must be registered into the mandatory Revlimid REMS ® program, and be willing and able to comply with the requirements of the REMs ® program. Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program
Exclusion Criteria:
- Known hypersensitivity to thalidomide or lenalidomide (if applicable).
- The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
- Known seropositive for human immunodeficiency virus (HIV). HIV testing is not required. Hepatitis testing is not required.
- Patients who have had a myocardial infarction within 6 months of enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
- Any serious medical condition laboratory abnormality or psychiatric illness that would prevent the subject from signing the consent form.
- Any condition, including laboratory abnormalities, that in the opinion of the investigator places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
- Patients with major surgery within 28 days prior to treatment.
- Patients with any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
- Patient has received an investigational agent or cytotoxic chemotherapy (excluding hydroxyurea) within 7 days of study entry.
- Patients with acute promyelocytic leukemia.
- Females who are pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lenalidomide and MEC chemotherapy
Lenalidomide is taken orally on a daily basis days 1-10.
Mitoxantrone, Etoposide, and Cytarabine are administered intravenously on a daily basis for days 4 through 8 of the treatment.
There is only one cycle of treatment in this study.
|
A Drug that interfere with the action of topoisomerase enzymes (topoisomerase I and II).
Topoisomerase enzymes control the manipulation of the structure of DNA necessary for replication.
Other Names:
Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA.
Other Names:
It may act by inhibiting the growth of new blood vessels (angiogenesis) in tumors, enhancing the status of the immune system, or decreasing cytokine and growth factor production
Other Names:
It interfere with cell reproduction
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete Response Rate
Time Frame: up to 45 days
|
Percentage of patients who have achieve CR or CRp after treatment.
|
up to 45 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients That Achieved ANC Recovery
Time Frame: up to 45 days
|
The number of patients that achieved a neutrophil count of > 500/mm3 for 3 days within 45 of starting treatment
|
up to 45 days
|
Number of Patients That Achieved Platelet Recovery
Time Frame: up to 45 days
|
The number of patients that achieved a stable platelet count > 20,000/mm3 for 3 days within 45 days of starting treatment
|
up to 45 days
|
Treatment-related Mortality
Time Frame: 50 days
|
Cumulative number of deaths not related to persistent or relapsed leukemia during treatment within 50 days of the start of treatment.
|
50 days
|
Transfusion Support: Number of Red Blood Cell and Platelet Transfusions
Time Frame: 50 days
|
Number of red blood cell and platelet transfusions received within the first 50 days of treatment
|
50 days
|
Overall Survival
Time Frame: Up to 3 years
|
Overall survival is defined as time from diagnosis of disease until date of death or censored on the last known date alive if patients are still alive.
|
Up to 3 years
|
Relapse-Free Survival
Time Frame: Up to 3 years
|
Relapse-Free Survival is defined as time from diagnosis of disease until date of relapse, death, or censored on the last known date alive if patients are still alive.Relapse is defined by morphological evidence of the original malignancy consistent with pre-treatment features.
|
Up to 3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Andrew Brunner, MD, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Hematologic Diseases
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Antiviral Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Etoposide
- Lenalidomide
- Cytarabine
- Mitoxantrone
Other Study ID Numbers
- 16-574
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on AML
-
H Scott BoswellTakedaTerminatedAML | AML, AdultUnited States
-
Technische Universität DresdenAbbVieActive, not recruitingRelapsed Adult AML | Refractory AMLGermany
-
Carbiogene Therapeutics Co. Ltd.Zhejiang Provincial People's HospitalRecruiting
-
National Research Center for Hematology, RussiaFederal Research Clinical Center of Federal Medical & Biological Agency,... and other collaboratorsRecruiting
-
Glycostem Therapeutics BVRecruiting
-
Etan OrgelAstellas Pharma Global Development, Inc.No longer available
-
Chinese PLA General HospitalNavy General Hospital, BeijingCompleted
-
University Hospital Inselspital, BerneWithdrawn
-
Turkish Leukemia Study GroupCompleted
Clinical Trials on Etoposide
-
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...UnitedHealthcareActive, not recruitingSmall Cell Lung CancerUnited States
-
University Hospital, BonnCompletedEpendymomas | Recurrent Brain Tumors | Supratentorial PNETs | MedulloblastomasGermany
-
Sun Yat-sen UniversityRecruitingSmall Cell Lung CarcinomaChina
-
Guizhou Medical UniversityUnknownSmall-cell Lung CancerChina
-
Third Military Medical UniversityUnknownExtensive-stage Small Cell Lung Cancer
-
Jiangsu HengRui Medicine Co., Ltd.Enrolling by invitation
-
CephalonWithdrawn
-
Qingdao UniversityUnknownProgression Free SurvivalChina
-
Annick DesjardinsAstraZenecaCompletedGlioblastoma | GliosarcomaUnited States
-
Shanghai Henlius BiotechRecruitingExtensive Stage Small Cell Lung CancerUnited States